Compositions and medical devices for controlled release of nitric oxide and methods of production thereof
US-9216198-B2 · Dec 22, 2015 · US
Magnetic nanocomposite for inhibiting/treating cancer and method for fabricating the same
US8992990B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8992990-B2 |
| Application number | US-79988710-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 4, 2010 |
| Priority date | Nov 2, 2009 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses a magnetic nanocomposite for inhibiting/treating cancer and a method for fabricating the same. The magnetic nanocomposite comprises a core formed of a plurality of magnetic nanoparticles made of ferric ferrous oxide (Fe 3 O 4 ); a shell made of a carboxy-functionalized polyaniline; and an anti-tumor medicine bound to the external surface of the shell. The method of the present invention fast fabricates the magnetic nanocomposite in a simple way. The medicine of the present invention has a longer half life and a better thermal stability. The present invention disperses the water-insoluble medicine in water uniformly to decrease the biological rejection. Moreover, the magnetic nanocomposite of the present invention is guided to the nidus by an external magnetic field to increase the local concentration of the medicine and provide an effective chemotherapy. Therefore, the present invention has competitive advantage over the conventional BCNU.
First claim
Opening claim text (preview).
What is claimed is: 1. A magnetic nanocomposite for inhibiting and treating cancer, comprising a core formed of a plurality of magnetic nanoparticles made of ferric ferrous oxide (Fe 3 O 4 ); a shell made of a carboxy-functionalized polyaniline and enveloping said core, wherein said carboxy-functionalized polyaniline contains carboxyl groups bonded to side chains of a polyaniline and has a structural formula:…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- A61K47/6923Primary
Human Necessities · mapped topic
- A61K47/48861Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8992990B2 cover?
- The present invention discloses a magnetic nanocomposite for inhibiting/treating cancer and a method for fabricating the same. The magnetic nanocomposite comprises a core formed of a plurality of magnetic nanoparticles made of ferric ferrous oxide (Fe 3 O 4 ); a shell made of a carboxy-functionalized polyaniline; and an anti-tumor medicine bound to the external surface of the shell. The method …
- Who is the assignee on this patent?
- Hua Mu-Yi, Yang Hung-Wei, Tsai Rung-Ywan, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/6923. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).